Benefits and risks of torasemide in congestive heart failure and essential hypertension.

D C Brater
Author Information
  1. D C Brater: Department of Medicine, Indiana University Medical Center, Indianapolis, USA.

Abstract

Torasemide is a lipophilic anilinopyridine sulphonylurea derivative that acts as a high ceiling loop diuretic and has been used for the treatment of both acute and chronic congestive heart failure (CHF) and hypertension. Torasemide is similar to other loop diuretics in terms of its mechanism of diuretic action; namely, blockade of Na+/K+/2Cl- cotransport in the thick ascending limb of the loop of Henle. It has high bioavailability (> 80%), as does bumetanide, but a longer elimination half-life (3 to 4 hours) than either bumetanide or furosemide (frusemide). In the treatment of chronic CHF, oral torasemide (5 to 20 mg/day) has been shown to be an effective diuretic. Patients treated with torasemide for up to 1 year have reduced bodyweight, improved pulmonary haemodynamics, and decreased CHF severity. Intravenous torasemide (20 to 60mg as a single dose) has been shown to be as effective as furosemide in the treatment of acute CHF, and resulted in significant diuresis, bodyweight loss, and improved pulmonary haemodynamics and exercise performance. 'Non-diuretic' dosages (2.5 to 5 mg/day) of oral torasemide have been used to treat essential hypertension, both as monotherapy and in combination with other antihypertensive agents. When used in these dosages, torasemide lowered diastolic blood pressure (DBP) to below 90mm Hg in 8 to 12 weeks in 70 to 80% of patients. With dose doubling, this level of efficacy occurred in more than 90% of hypertensive patients. Clinical trials have established that blood pressure can be maintained at this level for at least 1 year with low dose torasemide. Torasemide is well tolerated in dosages up to 20 mg/day for at least 1 year. The most commonly reported adverse effects are those associated with loop diuretics in general. These include transient hypokalaemia, hyperuricaemia, dizziness, headache, gastrointestinal disturbances, orthostatic hypotension and fatigue. Adverse effects are comparable with those of other diuretics and rarely necessitate drug withdrawal.

References

  1. Cardiology. 1994;84 Suppl 2:131-4 [PMID: 7954535]
  2. Clin Pharmacol Ther. 1983 Aug;34(2):181-9 [PMID: 6872412]
  3. Eur J Pharmacol. 1991 Nov 26;205(2):145-50 [PMID: 1812004]
  4. Eur Heart J. 1992 Dec;13 Suppl G:72-80 [PMID: 1486910]
  5. Drugs. 1991 Jan;41(1):81-103 [PMID: 1706990]
  6. Drugs. 1991;41 Suppl 3:14-22 [PMID: 1712712]
  7. Cardiology. 1994;84 Suppl 2:135-42 [PMID: 7954536]
  8. Cardiology. 1994;84 Suppl 2:36-42 [PMID: 7954543]
  9. Cardiovasc Drugs Ther. 1993 Jan;7 Suppl 1:11-21 [PMID: 8435373]
  10. Cardiology. 1994;84 Suppl 2:27-35 [PMID: 7954542]
  11. Clin Pharmacol Ther. 1995 Jun;57(6):601-9 [PMID: 7781259]
  12. J Hum Hypertens. 1988 Dec;2(4):265-8 [PMID: 3236329]
  13. Kidney Int. 1984 Aug;26(2):183-9 [PMID: 6503136]
  14. Naunyn Schmiedebergs Arch Pharmacol. 1985 Nov;331(2-3):275-82 [PMID: 4088324]
  15. Clin Pharmacol Ther. 1987 Aug;42(2):187-92 [PMID: 3608350]
  16. Arzneimittelforschung. 1988 Jan;38(1A):144-50 [PMID: 3370058]
  17. Drugs. 1991;41 Suppl 3:80-91 [PMID: 1712717]
  18. Arzneimittelforschung. 1988 Jan;38(1A):184-7 [PMID: 3285832]
  19. Drugs. 1995 Jan;49(1):121-42 [PMID: 7705212]
  20. Pharmacotherapy. 1994 Sep-Oct;14 (5):514-21 [PMID: 7997385]
  21. Br J Clin Pharmacol. 1983 Oct;16(4):391-7 [PMID: 6626433]
  22. Arzneimittelforschung. 1988 Jan;38(1A):164-6 [PMID: 3370063]
  23. Cardiology. 1994;84 Suppl 2:14-7 [PMID: 7954537]
  24. J Pharmacol Exp Ther. 1995 Mar;272(3):1076-81 [PMID: 7891318]
  25. J Pharmacol Exp Ther. 1989 Mar;248(3):1175-81 [PMID: 2703968]
  26. Cardiovasc Drugs Ther. 1993 Jan;7 Suppl 1:45-53 [PMID: 8435376]
  27. Arzneimittelforschung. 1988 Jan;38(1A):153-5 [PMID: 3370060]
  28. Eur Heart J. 1992 Dec;13 Suppl G:96-103 [PMID: 1486914]
  29. Prostaglandins Leukot Essent Fatty Acids. 1992 Feb;45(2):121-4 [PMID: 1561230]
  30. J Cardiovasc Pharmacol. 1993;22 Suppl 3:S32-9 [PMID: 7506335]
  31. Arch Intern Med. 1994 Sep 12;154(17):1905-14 [PMID: 8074594]
  32. Eur Arch Otorhinolaryngol. 1991;248(6):353-7 [PMID: 1930985]
  33. Eur J Clin Pharmacol. 1986;31 Suppl:35-42 [PMID: 3780838]
  34. Arzneimittelforschung. 1988 Jan;38(1A):190-3 [PMID: 3285833]
  35. Cardiology. 1994;84 Suppl 2:108-14 [PMID: 7954532]
  36. Br Heart J. 1994 Aug;72(2 Suppl):S40-3 [PMID: 7946757]
  37. Cardiovasc Drugs Ther. 1993 Jan;7 Suppl 1:63-8 [PMID: 8435378]
  38. Ann Intern Med. 1985 Mar;102(3):314-8 [PMID: 3970471]
  39. Drugs. 1985 Nov;30(5):427-43 [PMID: 3905337]
  40. Clin Pharmacol Ther. 1994 Jul;56(1):48-54 [PMID: 8033494]
  41. Eur J Clin Pharmacol. 1986;31 Suppl:43-7 [PMID: 3536531]
  42. Arch Int Pharmacodyn Ther. 1982 Nov;260(1):151-8 [PMID: 6762167]
  43. Ann Intern Med. 1979 Nov;91(5):744-5 [PMID: 496112]
  44. Ann Intern Med. 1984 Sep;101(3):370-7 [PMID: 6147109]
  45. Am J Ther. 1995 Jul;2(7):499-503 [PMID: 11850698]
  46. Clin Ther. 1993 Nov-Dec;15(6):1051-9 [PMID: 8111802]
  47. Hypertension. 1988 Mar;11(3 Pt 2):II16-20 [PMID: 3280487]
  48. J Clin Pharmacol. 1994 Nov;34(11):1083-7 [PMID: 7876400]
  49. J Cardiovasc Pharmacol. 1993;22 Suppl 3:S40-50 [PMID: 7506336]
  50. J Cardiovasc Pharmacol. 1993;22 Suppl 3:S11-23 [PMID: 7506333]
  51. Cardiology. 1994;84 Suppl 2:115-23 [PMID: 7954533]
  52. J Cardiovasc Pharmacol. 1993;22 Suppl 3:S24-31 [PMID: 7506334]
  53. Cardiology. 1994;84 Suppl 2:124-30 [PMID: 7954534]
  54. Arzneimittelforschung. 1988 Jan;38(1A):156-9 [PMID: 3370061]
  55. Am Heart J. 1994 Aug;128(2):352-7 [PMID: 8037103]
  56. Cardiology. 1994;84 Suppl 2:48-56 [PMID: 7954546]

MeSH Term

Antihypertensive Agents
Diuretics
Drug Interactions
Half-Life
Heart Failure
Hemodynamics
Humans
Hypertension
Sulfonamides
Torsemide

Chemicals

Antihypertensive Agents
Diuretics
Sulfonamides
Torsemide

Word Cloud

Created with Highcharts 10.0.0torasemideloopCHFTorasemidediureticusedtreatmenthypertensiondiuretics520mg/day1yeardosedosageshighacutechroniccongestiveheartfailure80%bumetanidefurosemideoralshowneffectivebodyweightimprovedpulmonaryhaemodynamicsessentialbloodpressurepatientslevelleasteffectslipophilicanilinopyridinesulphonylureaderivativeactsceilingsimilartermsmechanismactionnamelyblockadeNa+/K+/2Cl-cotransportthickascendinglimbHenlebioavailability>longereliminationhalf-life34hourseitherfrusemidePatientstreatedreduceddecreasedseverityIntravenous60mgsingleresultedsignificantdiuresislossexerciseperformance'Non-diuretic'2treatmonotherapycombinationantihypertensiveagentslowereddiastolicDBP90mmHg812weeks70doublingefficacyoccurred90%hypertensiveClinicaltrialsestablishedcanmaintainedlowwelltoleratedcommonlyreportedadverseassociatedgeneralincludetransienthypokalaemiahyperuricaemiadizzinessheadachegastrointestinaldisturbancesorthostatichypotensionfatigueAdversecomparablerarelynecessitatedrugwithdrawalBenefitsrisks

Similar Articles

Cited By